США - англійська - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt), fluticasone propionate (unii: o2gmz0lf5w) (fluticasone - unii:cut2w21n7u) - fluticasone propionate and salmeterol inhalation powder is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. fluticasone propionate and salmeterol inhalation powder should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an ics and long-acting beta2 -adrenergic agonist (laba). important limitation of use fluticasone propionate and salmeterol inhalation powder is not indicated for the relief of acute bronchospasm. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is also indicated to reduce exacerbations of copd in patients with a history of exacerbations. flutica

Європейський Союз - англійська - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - temybric ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).

Європейський Союз - англійська - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - elebrato ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Європейський Союз - англійська - EMA (European Medicines Agency)

glaxosmithkline trading services - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trelegy ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone furoate 100ug; vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg;   - powder for inhalation - 100mcg/25mcg - active: fluticasone furoate 100ug vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg   excipient: lactose monohydrate magnesium stearate - indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone furoate 200ug; vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg;   - powder for inhalation - 200mcg/25mcg - active: fluticasone furoate 200ug vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg   excipient: lactose monohydrate magnesium stearate - indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate.

Європейський Союз - англійська - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate, vilanterol - pulmonary disease, chronic obstructive - adrenergics and other drugs for obstructive airway diseases - asthma indication:relvar ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.copd indication:relvar ellipta is indicated for the symptomatic treatment of adults with copd with a fev1

Європейський Союз - англійська - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate, vilanterol trifenatate - asthma - adrenergics and other drugs for obstructive airway diseases - asthma indicationrevinty ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.copd indicationrevinty ellipta is indicated for the symptomatic treatment of adults with copd with a fev1

Європейський Союз - англійська - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate - rhinitis, allergic, seasonal; rhinitis, allergic, perennial - nasal preparations, corticosteroids - adults, adolescents (12 years and over) and children (6-11 years). avamys is indicated for the treatment of the symptoms of allergic rhinitis.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone furoate 27.5ug (per spray) - nasal spray suspension - 27.5 mcg - active: fluticasone furoate 27.5ug (per spray) excipient: benzalkonium chloride disodium edetate dihydrate dispersible cellulose glucose polysorbate 80 purified water - for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis in adults and children of ages 2 years and older.